Highest development stage: Phase 1 (as of 2022)

Development status: Active (as of 2022)

Combination therapy

Mechanism of Action/Target pathogen: DBOs bind reversibly to the beta-lactamase in the active site, inhibits class A, C, D and weakly inhibits penicillin binding protein 2 in Enterobacteriaceae

Additional information: Synthetic compound. Isopropyl ester prodrug of ETX-1317. In clinical development in fixed combination with cefpodoxime proxetil. Oral application